* This unified platform integrates sequence design, chemical modification, experimental validatio...
* The jointly developed AI model has passed comprehensive acceptance testing and is now operating...
* This milestone marks the first IND submission from XtalPi's proprietary pipeline, recently unve...
* Viva-Thera makes its public debut with four modalities pursuing HIV prevention, treatment and c...
SHENZHEN, China, Aug. 19, 2026 /PRNewswire/ -- Financial Highlights: * In the first half of 202...
BOSTON and SHENZHEN, China, June 10, 2026 /PRNewswire/ -- XtalPi (2228.HK), a leading platform in a...
BOSTON, May 29, 2026 /PRNewswire/ -- XtalPi (2228.HK), an AI- and robotics- powered drug discovery ...
SHENZHEN, China, May 4, 2026 /PRNewswire/ -- XtalPi (2228.HK), a leading AI- and robotics-powered i...
HONG KONG, March 25, 2026 /PRNewswire/ -- Financial Highlights: * Revenues for year 2025 were ...
CAMBRIDGE, Mass., March 13, 2026 /PRNewswire/ -- XtalPi Holdings Limited ("XtalPi", or the "Company...
SHANGHAI, Nov. 5, 2025 /PRNewswire/ -- Ailux, an innovator in AI-powered biologics and a wholly own...
SHENZHEN, China, Sept. 9, 2025 /PRNewswire/ -- XtalPi Inc. (Stock Code: 2228.HK) has announced that...
SHENZHEN, China, Aug. 27, 2025 /PRNewswire/ -- Key Highlights from the Financial Report: * Rev...
SHENZHEN, China, Aug. 27, 2025 /PRNewswire/ -- Key Highlights from the Financial Report: * Rev...
CAMBRIDGE, Mass., Aug. 20, 2025 /PRNewswire/ -- XtalPi announced on the 20th that it signed a Memor...
CAMBRIDGE, Mass., Aug. 18, 2025 /PRNewswire/ -- XtalPi Holdings Limited ("XtalPi", or the "Company"...
Strategic partnership leverages AI and robotics for novel therapeutics across oncology, immunology,...
CAMBRIDGE, Mass., June 30, 2025 /PRNewswire/ -- XtalPi (2228.HK), a leading global technology compa...
CAMBRIDGE, Mass. , June 23, 2025 /PRNewswire/ -- XtalPi, a global leader in AI- and robotics-powere...
CAMBRIDGE, Mass. and LIVERPOOL, United Kingdom, June 13, 2025 /PRNewswire/ -- XtalPi, a leading lif...